A genome wide association study on Newfoundland colorectal cancer patients’ survival outcomes

Xu, Wei; Xu, Jingxiong; Shestopaloff, Konstantin; Dicks, Elizabeth; Green, Jane; Parfrey, Patrick; Green, Roger; Savas, Sevtap

doi:10.1186/s40364-015-0031-6

Biomarker Research

Table 1 Baseline characteristics of the MSS/MSI-L colorectal, colon and rectal cancer patients investigated in this study

From: A genome wide association study on Newfoundland colorectal cancer patients’ survival outcomes

Characteristics	Entire cohort (n = 505)	%*	Colon cohort (n = 334)	%*	Rectal Cohort (n = 171)	%*	MSS/MSI-L cohort (n = 431)	%*
Sex
Female	198	39	141	42	57	33	158	37
Male	307	61	193	58	114	67	273	63
Age at diagnosis (median)	61.4 years, range: 20.7-75		62.25 years, range: 20.7-75		59.73 years, range: 33.64-75		62.12 years, range: 20.7-75
Histology
Non-mucinous	448	89	287	86	161	94	387	90
Mucinous	57	11	47	14	10	6	44	10
Location
Colon	334	66	334	100	0	0	274	64
Rectum	171	34	0	0	171	100	157	36
Stage
I	93	18	57	17	36	21	81	19
II	196	39	135	40	61	36	159	37
III	166	33	104	31	62	36	143	33
IV	50	10	38	11	12	7	48	11
Grade
Well/moderately differentiated	464	92	307	92	157	92	400	93
Poorly differentiated	37	7	24	7	13	8	27	6
Unknown	4	1	3	1	1	1	4	1
Vascular invasion
Absent	308	61	209	63	99	58	262	61
Present	159	31	107	32	52	30	137	32
Unknown	38	8	18	5	20	12	32	7
Lymphatic invasion
Absent	298	59	200	60	98	57	256	59
Present	167	33	112	34	55	32	144	33
Unknown	40	8	22	7	18	11	31	7
Familial risk
Low risk	250	50	161	48	89	52	218	51
High/moderate risk	255	50	173	52	82	48	213	49
MSI status
MSS/MSI-L	431	85	274	82	157	92	431	100
MSI-H	53	10	49	15	4	2	0	0
Unknown	21	4	11	3	10	6	0	0
BRAF Val600Glu mutation
Absent	411	81	263	79	148	87	377	87
Present	47	9	46	14	1	1	25	6
Unknown	47	9	25	7	22	13	29	7
Adjuvant chemotherapy status
Not given	224	44	174	52	50	29	189	44
Given	277	55	156	47	121	71	239	55
Unknown	4	1	4	1	0	0	3	1
Adjuvant 5-FU based chemotherapy status
Not given	230	46	179	54	51	30	193	45
Given	261	52	147	44	114	67	226	52
Unknown	14	3	8	2	6	4	12	3
Adjuvant radiotherapy status
Not given	364	72	307	92	57	33	302	70
Given	124	25	11	3	113	66	113	26
Unknown	17	3	16	5	1	1	16	4
OS status
Alive	334	66	229	69	105	61	272	63
Dead	170	34	105	31	65	38	158	37
Unknown	1	0	0	0	1	1	1	0
OS time_2010 (median)	6.36 years, range: 0.38-10.88		6.38 years, range: 0.38-10.88		6.3 years, range:1.64-10.65		6.32 years, range: 0.38-10.88
DFS status
No recurrence, metastasis or death	304	60	213	64	91	53	246	57
Recurrence, metastasis or death	200	40	121	36	79	46	184	43
Unknown	1	0	0	0	1	1	1	0
DFS time (median)	6 years, range: 0.22-10.88		6.22 years, range: 0.38-10.88		5.48 years, range:0.22-10.65		5.85 years, range: 0.22-10.88

5-FU: 5-fluorouracil, DFS: disease-free survival, MSI-L: microsatellite instability-low, MSS: microsatellite stable, OS: overall survival. *numbers rounded.

Back to article page

ISSN: 2050-7771

Contact us

General enquiries: journalsubmissions@springernature.com